Amicus Therapeutics is a little-known biopharmaceutical company that boasts some impressive discoveries and holdings. Despite only having 92 employees as of 2013, the company generates over 18 million dollars in revenue each year, with the potential for far more depending on the continued success of their newest research.
The focus of Amicus Therapeutics is on rare diseases, specifically, disorders known as lysosomal storage disorders. Their mission is to try and be a voice for those with a rare genetic condition such as Fabry disease. This research has earned them the title of “the broadest portfolio of small molecule pharmacological chaperones” in the industry according to the Royal Society of Chemistry.
What is most interesting about this company it is that it has operated successfully the last 15 years without having brought a product to market. 15 years later there is a hopeful candidate for the company in the form of Migalastat (trade name Galafold).
This pharmaceutical has been clinically shown to help patients suffering from Fabry disease and is currently undergoing FDA evaluation before being made available (http://blogwebpedia.com/amicus-therapeutics.html#.Wdf9t0yZP-Y). In addition to treating Fabry disease, initial trials have shown Galafold to have no serious side effects, even after four years of continuous use.
Having never bought a product to market may seem like frightening news for investors, but the ongoing support for the company paints a different picture (GoogleFinance). Over the last year, Amicus Therapeutics stock (ticker symbol: FOLD) has nearly tripled in value, bringing their market capitalization to over 2 billion dollars.
Investors can expect a considerable return on their investment when Galafold is approved by the FDA and makes it to market.